Cyclo Therapeutics Presents Preliminary Data From Phase 3 Study Of Trappsol Cyclo For Niemann-Pick Disease Type C1 At SSIEM Symposium; Topline Data Expected H1 2025
Portfolio Pulse from Benzinga Newsdesk
Cyclo Therapeutics presented preliminary data from its Phase 3 study of Trappsol Cyclo for Niemann-Pick Disease Type C1 at the SSIEM Symposium. Topline data from the study is expected in the first half of 2025.
September 05, 2024 | 1:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cyclo Therapeutics has shared preliminary data from its Phase 3 study of Trappsol Cyclo, targeting Niemann-Pick Disease Type C1. The full results are anticipated in the first half of 2025.
The presentation of preliminary data from a Phase 3 study is a significant milestone for Cyclo Therapeutics, as it indicates progress in their clinical trials. The anticipation of topline data in 2025 suggests potential future developments that could impact the stock positively.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100